EA201790721A1 - Инъекционный состав бупренорфина - Google Patents

Инъекционный состав бупренорфина

Info

Publication number
EA201790721A1
EA201790721A1 EA201790721A EA201790721A EA201790721A1 EA 201790721 A1 EA201790721 A1 EA 201790721A1 EA 201790721 A EA201790721 A EA 201790721A EA 201790721 A EA201790721 A EA 201790721A EA 201790721 A1 EA201790721 A1 EA 201790721A1
Authority
EA
Eurasian Patent Office
Prior art keywords
opioid
buprenorphine
treatment
controlled release
provides
Prior art date
Application number
EA201790721A
Other languages
English (en)
Other versions
EA033935B1 (ru
Inventor
Фредрик Тиберг
Маркус Йонссон
Иан Харвигссон
Original Assignee
Камурус Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Камурус Аб filed Critical Камурус Аб
Publication of EA201790721A1 publication Critical patent/EA201790721A1/ru
Publication of EA033935B1 publication Critical patent/EA033935B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение обеспечивает инъекционный жидкий состав с контролируемым высвобождением, содержащий: a) липидную матрицу с контролируемым высвобождением, содержащую по меньшей мере 50% триациллипидов; b) по меньшей мере один кислородсодержащий органический растворитель; c) по меньшей мере 16% по массе по меньшей мере одного активного агента, выбранного из бупренорфина и его солей, в расчете на свободное основание бупренорфина. В настоящем изобретении представлен также способ лечения боли, опиоидной поддерживающей терапии или лечения опиоидной зависимости посредством детоксикации и/или поддерживающей терапии, или лечения или профилактики симптомов отмены опиоидов и/или отмены кокаина, посредством инъекционного введения указанной жидкой композиции.
EA201790721A 2014-10-27 2015-10-27 Инъекционный состав бупренорфина EA033935B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1419091.2A GB201419091D0 (en) 2014-10-27 2014-10-27 Formulations
PCT/EP2015/074901 WO2016066655A1 (en) 2014-10-27 2015-10-27 Injectable buprenorphine formulation

Publications (2)

Publication Number Publication Date
EA201790721A1 true EA201790721A1 (ru) 2017-09-29
EA033935B1 EA033935B1 (ru) 2019-12-11

Family

ID=52103459

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790721A EA033935B1 (ru) 2014-10-27 2015-10-27 Инъекционный состав бупренорфина

Country Status (17)

Country Link
US (2) US20180015031A1 (ru)
EP (1) EP3212168A1 (ru)
JP (1) JP6768648B2 (ru)
KR (2) KR102541281B1 (ru)
CN (1) CN107205920B (ru)
AU (1) AU2015340661B2 (ru)
BR (1) BR112017008721A2 (ru)
CA (1) CA2964045C (ru)
CL (1) CL2017001024A1 (ru)
EA (1) EA033935B1 (ru)
GB (1) GB201419091D0 (ru)
IL (1) IL251413B2 (ru)
MX (1) MX2017005461A (ru)
MY (1) MY183540A (ru)
SG (1) SG11201703158WA (ru)
TW (1) TW201625250A (ru)
WO (1) WO2016066655A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
BR112019004923A2 (pt) * 2016-09-13 2019-06-04 Alar Pharmaceuticals Inc formulações de buprenorfina de liberação sustentada
KR20190083645A (ko) 2016-09-15 2019-07-12 카무러스 에이비 프로스타글란딘 유사체 제제
AU2017336199B2 (en) 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2023020608A1 (zh) * 2021-08-20 2023-02-23 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
US20100120811A1 (en) * 2008-07-17 2010-05-13 Peter Hanson Long-acting injectable analgesic formulations for animals
GB2469792A (en) 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
SI2877155T1 (sl) * 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法

Also Published As

Publication number Publication date
NZ730521A (en) 2023-11-24
US20210308041A1 (en) 2021-10-07
KR20170072237A (ko) 2017-06-26
EA033935B1 (ru) 2019-12-11
JP6768648B2 (ja) 2020-10-14
AU2015340661B2 (en) 2018-04-26
CN107205920A (zh) 2017-09-26
EP3212168A1 (en) 2017-09-06
US12029813B2 (en) 2024-07-09
CL2017001024A1 (es) 2017-11-10
KR102541281B1 (ko) 2023-06-13
AU2015340661A1 (en) 2017-04-20
TW201625250A (zh) 2016-07-16
IL251413B1 (en) 2023-01-01
SG11201703158WA (en) 2017-05-30
GB201419091D0 (en) 2014-12-10
MY183540A (en) 2021-02-25
CA2964045C (en) 2023-03-07
CN107205920B (zh) 2021-05-25
WO2016066655A1 (en) 2016-05-06
IL251413B2 (en) 2023-05-01
KR20230039767A (ko) 2023-03-21
CA2964045A1 (en) 2016-05-06
BR112017008721A2 (pt) 2018-01-30
IL251413A0 (en) 2017-05-29
US20180015031A1 (en) 2018-01-18
MX2017005461A (es) 2018-01-17
JP2017532354A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
EA201790721A1 (ru) Инъекционный состав бупренорфина
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
MX2019003790A (es) Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
CL2019001292A1 (es) Nuevos derivados de quinolina.
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2016002753A1 (es) Composición conservante de la madera
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
MX2016004035A (es) Formulaciones de espiro-isoxazolina de accion prolongada.
MX2019002190A (es) Uso de pridopidina para tratar distonías.
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
NZ709985A (en) Nitroxyl donors with improved therapeutic index
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112017004925A2 (pt) composição e método
CY1124016T1 (el) Φαρμακοτεχνικες μορφες οπιοειδων
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR112019003131A2 (pt) processo para preparar micropartículas contendo acetato de glatirâmero
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
EA033769B9 (ru) Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы